A new treatment for Duchenne muscular dystrophy (DMD) is set to be available to around 1,700 people in England following positive final draft guidance from NICE published today.
The medication will initially be offered only to those people with the highest clinical needs.
Working alongside people and communities is an essential tool in helping to improve the impact of our guidance and continuing to get the best care to people and communities, fast, while ensuring value for the taxpayer.
For the first time, the British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) have collaborated to develop a UK-wide asthma guideline.
A guide to the severity modifier and how it is leading to more positive recommendations overall from NICE. What is the severity modifier? Why has NICE introduced it? And what impact has it had on the health and care system?
How we make independent decisions on the cost and clinical effectiveness of medicines and treatments.
We explore the ongoing debate around NICE’s cost-effectiveness thresholds and what the future holds.
Dr Patterson, a GP working on the frontline of primary care, describes why he is encouraged by NICE's approval of tirzepatide (Mounjaro).
